Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.

Blood (2009) 114 (22): 743.

https://doi.org/10.1182/blood.V114.22.743.743

Published: 2009

Journal Articles

Evaluation of Prognostic Factors for Malignant Transformation of Monoclonal Gammopathy of Undetermined Significance

Federico Sackmann, Claudia Corrado, Isolda Fernandez, Miguel A Pavlovsky, Pablo Mountford, Astrid Pavlovsky, Miguel Pavlovsky, Mariel Alejandre, Marco Pizzolato, Santiago Pavlovsky, MD, PhD

Blood (2008) 112 (11): 5123.

https://doi.org/10.1182/blood.V112.11.5123.5123

Published: 2008

Journal Articles

Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience.

Carolina Pavlovsky, MD, Santiago Pavlovsky, MD PhD, Maria L. Pardo, MD, Sandra Sapia, MD, Mariela Monreal, MD, Claudia Corrado, MDd, Miguel A. Pavlovsky, MD, Isolda Fernandez, MD, Mariana Juni, MS

Blood (2006) 108 (11): 4968.

https://doi.org/10.1182/blood.V108.11.4968.4968

Published: 2006

Journal Articles

Risk-Oriented Therapy in Adults Previously Untreated Hodgkin’s Lymphoma (HL) with ABVD Followed by Involved Field Radiotherapy (IFRT). Final Results of the Argentinian Group for Treatment of Acute Leukemia (GATLA) Phase III Study.

Santiago Pavlovsky, MD, PhD, Claudia S. Corrado, MD, Miguel A. Pavlovsky, MD, Virginia Prates, MD, Lucia Zoppegno, MD, Mario Giunta, MD, Ider Cerutti, MD, Elsa Palomino, MD, Fernando Pagani, MD, Francisco Lastiri, MD, Maria C. Narbaitz, MD, Fernando Cavagnaro, MD, Graciela Avila, MD

Blood (2006) 108 (11): 2474.

https://doi.org/10.1182/blood.V108.11.2474.2474

Published: 2006

Journal Articles

Combined Chemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience.

Santiago Pavlovsky, MD, PhD, Carolina Pavlovsky, MD, Laura Pardo, MD, Sandra Sapia, MD, Isolda I. Fernandez, MD, Mariana Juni

Blood (2005) 106 (11): 5033.

https://doi.org/10.1182/blood.V106.11.5033.5033

Published: 2005

Journal Articles

Impact of FLT3 Mutational Status as Prognostic Factor in Acute Myeloid Leukemia Patients from Argentina and Uruguay.

Isabel Giere, PhD, Angel Chacon, MD, Rosario Uriarte, PhD, Virginia Lombardi, PhD, Isolda Fernandez, MD, Fernanda Garcia Reinoso, Ph.D, Rosana Bonomi, MD, Maria Zubillaga, PhD, Hugo Giordano, MD, Laura Pardo, PhD, Sandra Sapia, MD, Mariela Monreal, Ph.D, Lem Martinez, MD, Santiago Pavlovsky, MD, PhD

Blood (2005) 106 (11): 4494.

https://doi.org/10.1182/blood.V106.11.4494.4494

Published: 2005

Journal Articles

CD38 Expression Has an Important Value among Prognostic Factors in Chronic Lymphocytic Leukemia (CLL): A Multivariate Analysis in 160 Patients.

Carolina Pavlovsky, MD, Miguel A. Pavlovsky, MD, Maria L. Pardo, MD, Sandra Sapia, MD, Pablo Mountford, MD, Isolda I. Fernandez, MD, Claudia S. Corrado, MD, Mariana Juni Statistics, Santiago Pavlovsky, MD PhD

Blood (2004) 104 (11): 4779.

https://doi.org/10.1182/blood.V104.11.4779.4779

Published: 2004

Journal Articles

Risk-Adapted Therapy in Adults Previously Untreated Hodgkin’s Lymphoma (HL) with ABVD Followed by Involved Field Radiotherapy (IFRT).

Santiago Pavlovsky, MD PhD, Claudia S. Corrado, MD, Miguel A. Pavlovsky, MD, Mario Giunta, MD, Lucia Zoppegno, MD, Virginia Prates, MD, Francisco Lastiri, PhD, Ider Cerutti, MD, Maria C. Narbaitz, MD, Silvia Rudoy, MD, Fernando Cavagnaro, MD, Alejandra Kurchan, MD, Elsa Palomino, MD, Cesar Campo, MD

Blood (2004) 104 (11): 1310.

https://doi.org/10.1182/blood.V104.11.1310.1310

Published: 2004

NARROW

Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.

Evaluation of Prognostic Factors for Malignant Transformation of Monoclonal Gammopathy of Undetermined Significance

Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience.

Risk-Oriented Therapy in Adults Previously Untreated Hodgkin’s Lymphoma (HL) with ABVD Followed by Involved Field Radiotherapy (IFRT). Final Results of the Argentinian Group for Treatment of Acute Leukemia (GATLA) Phase III Study.

Combined Chemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience.

Impact of FLT3 Mutational Status as Prognostic Factor in Acute Myeloid Leukemia Patients from Argentina and Uruguay.

CD38 Expression Has an Important Value among Prognostic Factors in Chronic Lymphocytic Leukemia (CLL): A Multivariate Analysis in 160 Patients.

Risk-Adapted Therapy in Adults Previously Untreated Hodgkin’s Lymphoma (HL) with ABVD Followed by Involved Field Radiotherapy (IFRT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only